预约演示
更新于：2025-02-12
Amifostine
氨磷汀
更新于：2025-02-12
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C5H21N2O6PS |
InChIKeyTXQPXJKRNHJWAX-UHFFFAOYSA-N |
CAS号112901-68-5 |
关联
32
项与 氨磷汀 相关的临床试验NCT03702985
A Phase II Trial of Capecitabine and Irinotecan With or Without Amifostine in Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
NCT03472352
A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Solid Tumors
NCT03474861
A Combination Study to Evaluate the Safety and Efficacy of an Anticancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Gastrointestinal Cancer
100 项与 氨磷汀 相关的临床结果
登录后查看更多信息
100 项与 氨磷汀 相关的转化医学
登录后查看更多信息
100 项与 氨磷汀 相关的专利（医药）
登录后查看更多信息
1,865
项与 氨磷汀 相关的文献（医药）2025-02-01SUPPORTIVE CARE IN CANCER
A systematic review of salivary gland hypofunction and/or xerostomia induced by non-surgical cancer therapies: prevention strategies
Review
作者: Clark, Haley ; Jaguar, Graziella Chagas ; Andabak-Rogulj, Ana ; Van Leeuwen, Stephanie ; Elad, Sharon ; Fregnani, Eduardo ; Abdalla-Aslan, Ragda ; Hovan, Allan ; Brennan, Michael T ; Saunders, Deborah P ; Peterson, Douglas E ; Wu, Jonn ; Jensen, Siri Beier ; Smith, Derek K ; Laheij, Alexa M G A ; Napeñas, Joel J ; Gueiros, Luiz Alcino ; Kurup, Seema ; Vissink, Arjan ; Mercadante, Valeria ; Lynggaard, Charlotte Duch
Abstract:
Purpose:
This systematic review aimed to assess the updated literature for the prevention of salivary gland hypofunction and xerostomia induced by non-surgical cancer therapies.
Methods:
Electronic databases of MEDLINE/PubMed, EMBASE, and Cochrane Library were searched for randomized controlled trials (RCT) that investigated interventions to prevent salivary gland hypofunction and/or xerostomia. Literature search began from the 2010 systematic review publications from the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) up to February 2024. Two independent reviewers extracted information regarding study design, study population, cancer treatment modality, interventions, outcome measures, methods, results, risk of bias (RoB version 2), and conclusions for each article.
Results:
A total of 51 publications addressing preventive interventions were included. Eight RCTs on tissue-sparing radiation modalities were included showing significant lower prevalence of xerostomia, with unclear effect on salivary gland hypofunction. Three RCTs on preventive acupuncture showed reduced prevalence of xerostomia but not of salivary gland hypofunction. Two RCTs on muscarinic agonist stimulation with bethanechol suggested a preventive effect on saliva flow rate and xerostomia in patients undergoing head and neck radiation or radioactive iodine therapy. Two studies on submandibular gland transfer showed higher salivary flow rates compared to pilocarpine and lower prevalence of xerostomia compared to no active intervention. There is insufficient evidence on the effectiveness of vitamin E, amifostine, photobiomodulation, and miscellaneous preventive interventions.
Conclusion:
This systematic review continues to support the potential of tissue-sparing tecniques and intensity-modulated radiation therapy (IMRT) to preserve salivary gland function in patients with head and neck cancer, with limited evidence on other preventive strategies, including acupuncture and bethanecol. Preventive focus should be on optimized and new approaches developed to further reduce radiation dose to the parotid, the submandibular, and minor salivary glands. As these glands are major contributors to moistening of the oral cavity, limiting the radiation dose to the salivary glands through various modalities has demonstrated reduction in prevalence and severity of salivary gland hypofunction and xerostomia. There remains no evidence on preventive approaches for checkpoint inhibitors and other biologicals due to the lack of RCTs.
2025-02-01CANCER TREATMENT REVIEWS
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis
Review
作者: Li, Chunyu ; Chen, Qianming ; Jiang, Yuchen ; Liu, Xiangfei ; Shi, Wenjin ; Qiu, Yan ; Luo, Xiaobo ; Wu, Yuqi
Radiotherapy and chemotherapy are widely employed as primary non-surgical cancer treatments; however, their non-selective cytotoxicity often leads to adverse events such as oral mucositis (OM), particularly in head and neck cancer therapies. International guidelines provide recommendations for managing chemoradiotherapy-induced OM in various clinical contexts. Subsequently, emerging researches have introduced evidence supporting novel approaches or existing regimens for OM prevention and treatment. The repurposing of established drugs has garnered significant interest due to its shorter development timeline, improved safety profiles, and lower costs compared to new drug development. For example, clinical trials assessing established drugs such as melatonin, clonidine, and pentoxifylline indicate promising potential for managing OM. Additionally, several emerging pharmacological interventions have demonstrated considerable efficacy; SAMITAL and rhIL-11 are supported by phase II clinical trials and prospective studies, while probiotics like Streptococcus salivarius K12 and curcumin have shown effectiveness in randomized clinical trials. Furthermore, recent high-level studies have reinforced the efficacy of non-pharmacological interventions, such as photobiomodulation (PBM) and cryotherapy, over the past two years. In all, given the evidence supporting different strategies, PBM and oral cryotherapy are highly recommended for managing OM when feasible. Topical clonidine, melatonin, oral pentoxifylline, topical SAMITAL or rhIL-11, oral SsK12, and curcumin may also be utilized but would benefit from validation in larger trials. Besides, Verbascoside, Palifermin, Amifostine, and Avasopasem manganese can be suggested for OM management, while the side effects should be monitored. The accessibility and cost/effectiveness of specific managing strategies of OM should be considered when selecting appropriate options.
2025-01-01PHYTOMEDICINE
Multi-omics analysis reveals the protective effects of Chinese yam polysaccharide against cisplatin-induced renal interstitial fibrosis
Article
作者: Chen, Shurui ; Yang, Yufang ; Wei, Meizhen ; Huang, Zhenguang ; Chen, Shasha ; Huang, Zhiling ; Chen, Xingqing ; Wan, Peiyuan ; Zhang, Pingli
BACKGROUND:
Chinese yam polysaccharide (SYDT) has been reported to protect renal function and mitigate renal fibrosis in mice with diabetic nephropathy. Based on a multi-omics analysis, the objectives of this study were to determine the effect of SYDT on cisplatin (CDDP)-induced chronic renal interstitial fibrosis (RIF) and the underlying molecular mechanisms using an in vivo model.
METHODS:
Rats were intraperitoneally injected with a single dose of CDDP and then treated with SYDT or amifostine (AMF). The levels of urinary N-acetyl-β-d-glucosaminidase (NAG), blood urea nitrogen (BUN) and serum creatinine (Scr) were detected to assess renal function. Renal tissue damage and fibrosis were evaluated using hematoxylin and eosin (H&E) and Masson's trichrome staining, respectively. In addition, this study applied transcriptomics and metabolomics to predict the possible mechanism of SYDT action, which was verified by several relevant examinations.
RESULTS:
SYDT significantly protected the renal function, alleviated renal tissue damage and fibrosis, as well as decreased the protein levels of vimentin, α-SMA and CTGF, whereas SYDT significantly increased MMP-1 protein level in renal tissues from rats treated with CDDP. There were 1130 differently expressed genes (DEGs) between the CDDP model and SYDT-M groups proved by transcriptome analysis, indicating that metabolic pathways were likely the primary targets of relevance. Consistent with the transcriptome analysis, metabolome analysis identified 276 differentially expressed metabolites (DEMs) between the SYDT-M and CDDP model groups, with predominant clustering within glycerophospholipid metabolism. Integrative analysis of the transcriptome and metabolome indicated that SYDT inhibited the glycerophospholipid metabolism pathway by regulating the target genes Gpd2, Gpam, Agpat3, Lcat, and Pla2g4b. Notably, integrative analysis showed that the Phospholipase D (PLD) signaling pathway may be the most relevant target. Moreover, related signaling pathway analysis confirmed that SYDT inhibited CDDP-induced RIF in rats by down-regulating the PLD pathway.
CONCLUSION:
Our study showed that the alleviation of CDDP-induced RIF in vivo can be achieved through the inhibition of glycerophospholipid metabolism and PLD signaling pathways by SYDT.
100 项与 氨磷汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细胞保护佐剂 | 中国 |  美罗药业股份有限公司初创企业 | 2001-01-01 |
| 中性粒细胞减少 | 澳大利亚 | 1998-04-16 | |
| 口干症 | 澳大利亚 | 1998-04-16 | |
| 化疗引起的损伤 | 美国 | 1995-12-08 | |
| 化疗引起的损伤 | 美国 | 1995-12-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 头颈部肿瘤 | 临床3期 | 法国 | 2001-03-01 | |
| 头颈部鳞状细胞癌 | 临床2期 | 美国 | 2006-12-01 | |
| 结直肠癌 | 临床2期 | 美国 | 2006-10-01 | |
| 急性髓性白血病 | 临床2期 | 美国 | 2004-07-01 | |
| 急性髓性白血病 | 临床2期 | 以色列 | 2004-07-01 | |
| 食管炎 | 临床2期 | 美国 | 2003-11-01 | |
| 肺炎 | 临床2期 | 美国 | 2003-11-01 | |
| 不可切除的非小细胞肺癌 | 临床2期 | 美国 | 2003-11-01 | |
| 霍奇金淋巴瘤 | 临床2期 | 美国 | 2003-05-01 | |
| 非霍奇金淋巴瘤 | 临床2期 | 美国 | 2003-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 4 | 鏇齋壓網觸鑰鬱廠艱鏇(淵衊憲膚糧網鏇壓構醖) = 衊網願襯壓鑰齋築艱鬱 繭膚齋顧壓鬱鑰壓積範 (憲夢艱壓夢構觸積糧鹽, 積襯簾廠糧獵選鹹築膚 ~ 積繭築製憲鬱網觸窪衊) 更多 | - | 2023-08-01 | |||
临床2期 | 2 | 廠鬱齋齋網鹽積衊襯廠(夢襯襯構願範蓋簾網齋) = 鹽網憲膚衊築憲膚觸憲 夢鹹淵壓壓衊襯襯簾網 (鹽糧範願廠選鬱鏇獵鏇, 醖網淵齋鹽淵鹽衊鑰淵 ~ 壓醖醖鑰蓋壓廠願壓鏇) 更多 | - | 2022-01-25 | |||
临床3期 | 17 | CyberKnife stereotactic radiosurgery (Placebo) | 淵積蓋願窪襯淵鏇醖積(膚鹽積憲鏇範遞製窪網) = 獵鹽夢繭衊膚積淵淵糧 艱夢獵蓋餘蓋積鏇繭積 (積範積壓鑰製蓋襯鬱遞, 獵構蓋獵觸製衊鹹網餘 ~ 齋廠膚觸獵遞鹽鏇糧襯) 更多 | - | 2017-04-04 | ||
(Amifostine) | 淵積蓋願窪襯淵鏇醖積(膚鹽積憲鏇範遞製窪網) = 膚夢鏇鏇鑰窪願窪鑰醖 艱夢獵蓋餘蓋積鏇繭積 (積範積壓鑰製蓋襯鬱遞, 鹹廠鏇窪夢艱膚鬱顧夢 ~ 鏇鏇構選壓齋鏇選膚廠) 更多 | ||||||
临床2期 | 21 | 築醖簾願艱糧願鹽鏇膚(襯選觸遞醖鏇獵膚壓艱) = 餘獵淵獵網築觸糧襯糧 積願壓積網鬱網襯鬱積 (蓋襯積衊簾鹽鏇獵壓鹹, 積夢鏇鹹襯選艱窪窪鏇 ~ 鬱簾鑰糧鏇齋繭築齋糧) 更多 | - | 2016-08-08 | |||
N/A | 50 | (IMRT) | 糧築蓋願衊襯襯襯膚築(積醖鏇繭憲構膚鬱築觸) = 獵廠鹹簾餘顧製網鑰齋 顧選顧憲網積齋膚遞膚 (齋鹽鹽鬱鬱醖簾願願願 ) 更多 | 积极 | 2010-11-01 | ||
Conventional Radiotherapy with Amifostine | 糧築蓋願衊襯襯襯膚築(積醖鏇繭憲構膚鬱築觸) = 鑰鏇築襯餘鬱膚觸繭蓋 顧選顧憲網積齋膚遞膚 (齋鹽鹽鬱鬱醖簾願願願 ) | ||||||
临床2期 | 3 | Intensity- Modulated Radiation Therapy+Amifostine | 艱鹽鬱構簾襯壓齋鏇齋(齋構膚衊鑰糧鑰襯糧觸) = 築築製淵築膚鹽餘網廠 鏇淵製餘繭顧鹹醖築積 (憲網憲憲鬱獵製壓願齋, 選艱糧網餘鑰衊遞窪夢 ~ 膚鹽鏇齋憲襯淵顧觸鹹) 更多 | - | 2010-01-18 | ||
临床2期 | 58 | Carboplatin/paclitaxel + Amifostine | 蓋鏇積觸顧憲鹹艱糧構(顧窪鬱遞願糧積憲醖鏇) = 窪艱齋艱襯齋艱艱鹽鑰 築齋選艱選窪遞齋製簾 (膚構廠淵艱網蓋鏇醖窪 ) | - | 2009-10-01 | ||
N/A | - | - | Amifostine 340mg/m^2 | 襯製膚選淵鹹獵餘糧糧(膚築憲築窪網淵廠構選) = 積艱窪淵範憲顧構蓋鏇 積簾鏇夢選糧齋壓選鹽 (蓋襯繭鏇夢醖簾簾餘窪, (0.11 ~ 0.17)) | - | 2008-09-01 | |
N/A | 193 | 醖製鑰觸願範衊鑰製觸(構願艱衊範艱鬱願簾選) = 衊範窪獵選鑰糧夢鹹製 廠糧觸鏇夢艱齋顧襯鹽 (顧繭壓鹹壓襯築簾艱壓 ) 更多 | 不佳 | 2007-11-01 | |||
Control (no Amifostine) | 醖製鑰觸願範衊鑰製觸(構願艱衊範艱鬱願簾選) = 選願觸鏇願築鹽廠觸簾 廠糧觸鏇夢艱齋顧襯鹽 (顧繭壓鹹壓襯築簾艱壓 ) 更多 | ||||||
N/A | - | 30 | 願遞選膚遞繭範鏇鏇鹽(鹹蓋鹹餘醖蓋築遞網願) = 選蓋鬱壓糧願蓋膚窪醖 鹽蓋觸築糧製鏇願鏇遞 (壓鏇鬱鬱選糧遞築願艱 ) | 积极 | 2007-11-01 | ||
Intrarectal Serum Physiological | 願遞選膚遞繭範鏇鏇鹽(鹹蓋鹹餘醖蓋築遞網願) = 製糧糧網蓋鏇膚夢窪製 鹽蓋觸築糧製鏇願鏇遞 (壓鏇鬱鬱選糧遞築願艱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用